These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33263045)

  • 21. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension].
    Tao XC; Peng WH; Xie WM; Wan J; Liu M; Gao L; Gao Q; Zhang S; Zhai ZG; Wang C
    Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(6):437-441. PubMed ID: 32146766
    [No Abstract]   [Full Text] [Related]  

  • 23. MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction.
    Jensen J; Schou M; Kistorp C; Faber J; Hansen TW; Jensen MT; Andersen HU; Rossing P; Vilsbøll T; Jørgensen PG
    Cardiovasc Diabetol; 2020 Oct; 19(1):180. PubMed ID: 33066783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes.
    Smith J; Halse KG; Damm P; Lindegaard ML; Amer-Wåhlin I; Hertel S; Johansen M; Mathiesen ER; Nielsen LB; Goetze JP
    Biomark Med; 2013 Feb; 7(1):139-46. PubMed ID: 23387495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia.
    Masiá M; Papassotiriou J; Morgenthaler NG; Hernández I; Shum C; Gutiérrez F
    Clin Chem; 2007 Dec; 53(12):2193-201. PubMed ID: 17951293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease.
    von Haehling S; Papassotiriou J; Hartmann O; Doehner W; Stellos K; Geisler T; Wurster T; Schuster A; Botnar RM; Gawaz M; Bigalke B
    Clin Sci (Lond); 2012 Nov; 123(10):601-10. PubMed ID: 22690794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of MR-proANP and copeptin for sepsis diagnosis after burn injury.
    Gille J; Schmidt J; Kremer T; Sablotzki A
    J Crit Care; 2019 Aug; 52():149-155. PubMed ID: 31075618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
    Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
    J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.
    Gohar A; Rutten FH; den Ruijter H; Kelder JC; von Haehling S; Anker SD; Möckel M; Hoes AW
    Eur J Heart Fail; 2019 Oct; 21(10):1219-1227. PubMed ID: 31209992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.
    Miller WL; Hartman KA; Grill DE; Struck J; Bergmann A; Jaffe AS
    Heart; 2012 Mar; 98(5):389-94. PubMed ID: 22194151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension.
    Kriechbaum SD; Wiedenroth CB; Peters K; Barde MA; Ajnwojner R; Wolter JS; Haas M; Roller FC; Guth S; Rieth AJ; Rolf A; Hamm CW; Mayer E; Keller T; Liebetrau C
    Biomarkers; 2020 Nov; 25(7):578-586. PubMed ID: 32901511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory morbidity in preterm infants predicted by natriuretic peptide (MR-proANP) and endothelin-1 (CT-proET-1).
    Gerull R; Neumann RP; Atkinson A; Bernasconi L; Schulzke SM; Wellmann S
    Pediatr Res; 2022 May; 91(6):1478-1484. PubMed ID: 33958715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.
    Krüger S; Papassotiriou J; Marre R; Richter K; Schumann C; von Baum H; Morgenthaler NG; Suttorp N; Welte T;
    Intensive Care Med; 2007 Dec; 33(12):2069-78. PubMed ID: 17938883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 36. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
    Charitakis E; Walfridsson H; Alehagen U
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study.
    Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Kamstrup PR; Faber J; Køber L; Schou M
    Glob Heart; 2020 Mar; 15(1):25. PubMed ID: 32489798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refined balloon pulmonary angioplasty-A therapeutic option in very elderly patients with chronic thromboembolic pulmonary hypertension.
    Roik M; Wretowski D; Łabyk A; Irzyk K; Lichodziejewska B; Dzikowska-Diduch O; Piotrowska-Kownacka D; Pruszczyk P
    J Interv Cardiol; 2017 Jun; 30(3):249-255. PubMed ID: 28474349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
    Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
    ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
    Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
    Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.